According to a new report, published by KBV research, The Global Leadless Pacemakers Market size is expected to reach $827.7 million by 2030, rising at a market growth of 15.2% CAGR during the forecast period.
The Micra Transcatheter Pacing System segment is leading the Global Leadless Pacemakers Market, By Type in 2022 thereby achieving a market value of $612.9 million by 2030. Because of its minimally invasive nature, the implantation of the micra pacemaker typically results in less pain, shorter recovery times, and minimal scarring. Patients can often resume normal activities more quickly after the procedure. Despite its small size, the micra pacemaker is equipped with a long-lasting battery, which can provide reliable pacing for several years before requiring replacement. Patients with the micra pacing system often experience an improved quality of life due to the reduced risk of complications, less pain, and the elimination of visible scars associated with traditional pacemakers.
The Outpatient Facilities segment is showcasing a CAGR of 20.1% during (2023 - 2030). Outpatient facilities can perform leadless pacemaker implantations efficiently, often in a dedicated cardiac catheterization lab. The streamlined workflow minimizes the time patients spend at the facility. Outpatient facilities can offer patients the convenience of undergoing leadless pacemaker procedures without the need for prolonged hospitalization. This can be particularly appealing to patients seeking a more convenient and patient-centered approach to healthcare. Patients undergoing leadless pacemaker implantation in outpatient facilities can typically return to their daily activities faster. This can enhance the patient’s experience and contribute to the reputation of the facility.
The North America region dominated the Global Leadless Pacemakers Market, By Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $384.3 million by 2030. The Europe market is anticipated to grow at a CAGR of 14.9% during (2023 - 2030). Additionally, The Asia Pacific market would witness a CAGR of 16.7% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/leadless-pacemakers-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd, Integer Holdings Corporation, MicroPort Scientific Corporation, Osypka AG, Terumo Corporation, and EBR Systems, Inc.
By Type
By End-use
By Geography
Companies Profiled
Unique Offerings 
